ZA825384B - Orally administrable pharmaceutical compositions - Google Patents

Orally administrable pharmaceutical compositions

Info

Publication number
ZA825384B
ZA825384B ZA825384A ZA825384A ZA825384B ZA 825384 B ZA825384 B ZA 825384B ZA 825384 A ZA825384 A ZA 825384A ZA 825384 A ZA825384 A ZA 825384A ZA 825384 B ZA825384 B ZA 825384B
Authority
ZA
South Africa
Prior art keywords
dosage form
pharmaceutical compositions
anionic polymer
orally administrable
administrable pharmaceutical
Prior art date
Application number
ZA825384A
Other languages
English (en)
Inventor
John Rhodes
Brian Kenneth Evans
Original Assignee
Tillott J B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10523624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA825384(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillott J B Ltd filed Critical Tillott J B Ltd
Publication of ZA825384B publication Critical patent/ZA825384B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA825384A 1981-07-31 1982-07-27 Orally administrable pharmaceutical compositions ZA825384B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8123573 1981-07-31

Publications (1)

Publication Number Publication Date
ZA825384B true ZA825384B (en) 1983-05-25

Family

ID=10523624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA825384A ZA825384B (en) 1981-07-31 1982-07-27 Orally administrable pharmaceutical compositions

Country Status (14)

Country Link
US (2) US5541170A (de)
EP (1) EP0097651B1 (de)
JP (1) JPS58501174A (de)
AT (1) ATE17189T1 (de)
AU (1) AU551173B2 (de)
CA (1) CA1172570A (de)
DE (1) DE3268277D1 (de)
DK (1) DK158931C (de)
FI (1) FI85216C (de)
GB (1) GB2123695B (de)
IT (1) IT1149328B (de)
NO (1) NO159696C (de)
WO (1) WO1983000435A1 (de)
ZA (1) ZA825384B (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (de) * 1980-03-20 1982-03-11
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
DE3775880D1 (de) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JPH01299226A (ja) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd サラゾスルファピリジン腸溶顆粒
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
NL9002336A (nl) * 1990-10-24 1992-05-18 Leuven K U Res & Dev Bekledings- of matrixmateriaal voor geneesmiddelen.
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
WO1992016214A1 (en) * 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
DK0667148T3 (da) * 1992-11-06 2002-07-22 Hisamitsu Pharmaceutical Co Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
SE9401738D0 (sv) * 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
AU2521797A (en) * 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
KR20010075144A (ko) * 1998-09-21 2001-08-09 오오쯔키 히로시 활성형 글리시리진의 생체이용률을 높이기 위한경구투여용 약물송달시스템
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
US6962717B1 (en) 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
EP1183014B1 (de) 1999-06-14 2003-10-08 Cosmo S.p.A. Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
EP1197228A4 (de) 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co Arzneimittel für die behandlung von kolorektalem krebs
RU2153340C1 (ru) * 1999-12-14 2000-07-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтический состав, регулирующий метаболические процессы, и способ его получения
US20030114349A1 (en) * 2000-04-27 2003-06-19 The Procter & Gamble Company Coating composition for solid bodies
BR0112393A (pt) 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
RU2187307C1 (ru) * 2001-10-15 2002-08-20 Сыров Кирилл Константинович Твердые стабильные лекарственные формы преднизолона
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
WO2005021013A1 (ja) 2003-09-01 2005-03-10 Earthus, Inc. β−ヒドロキシ短〜中鎖脂肪酸重合体
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005072113A2 (en) * 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
EP2803357B1 (de) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesehemmer
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
KR101123001B1 (ko) * 2004-09-01 2012-03-13 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007025146A2 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US20110144188A1 (en) * 2006-06-06 2011-06-16 Antibe Therapeutics Inc. Salts of trimebutine and n-desmethyl trimebutine
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
ES2552723T3 (es) 2008-05-06 2015-12-01 Dexcel Pharma Technologies Ltd. Formulación de bencimidazol estable
CN102238868A (zh) * 2008-10-03 2011-11-09 福尔克博士药物有限责任公司 使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
WO2011045775A1 (en) 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited A delayed release pharmaceutical composition of mesalamine
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP6294457B2 (ja) 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (de) 2013-12-20 2016-10-26 The Broad Institute, Inc. Kombinationstherapie mit neoantigen-impfstoff
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
US9827343B2 (en) 2015-11-02 2017-11-28 Pura Scents, Inc. Scent dispensation and fluid level sensing
USD816506S1 (en) 2015-11-02 2018-05-01 Pura Scents, Inc. Vial for a scent dispenser
USD809116S1 (en) 2015-11-02 2018-01-30 Pura Scents Dispenser
EP3446119A1 (de) 2016-04-18 2019-02-27 The Broad Institute Inc. Verbesserte hla-epitopvorhersage
EP3257501A1 (de) 2016-06-14 2017-12-20 Tillotts Pharma AG Aus mehreren einzeleinheiten zusammengesetzte dosierungsform mit einem kern aus individuellen kerneinheiten, die mit mukoadhäsivem material bedeckt sind, sowie einer enterischen kernbeschichtung
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
PH10958A (en) * 1967-08-18 1977-10-13 Abbott Lab Tablet preparation
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition
US4190716A (en) * 1978-12-20 1980-02-26 Dynapol Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
JPS57500432A (de) * 1980-03-20 1982-03-11
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap

Also Published As

Publication number Publication date
JPH0414083B2 (de) 1992-03-11
AU551173B2 (en) 1986-04-17
FI85216C (fi) 1992-03-25
DK158931C (da) 1990-12-31
NO159696B (no) 1988-10-24
EP0097651B1 (de) 1986-01-02
US5541171A (en) 1996-07-30
WO1983000435A1 (en) 1983-02-17
AU8732482A (en) 1983-02-22
ATE17189T1 (de) 1986-01-15
DE3268277D1 (en) 1986-02-13
DK158931B (da) 1990-08-06
CA1172570A (en) 1984-08-14
GB8322387D0 (en) 1983-09-21
GB2123695B (en) 1985-05-01
FI85216B (fi) 1991-12-13
DK128283D0 (da) 1983-03-21
FI833099A0 (fi) 1983-08-31
US5541170A (en) 1996-07-30
JPS58501174A (ja) 1983-07-21
EP0097651A1 (de) 1984-01-11
GB2123695A (en) 1984-02-08
IT8248908A0 (it) 1982-07-29
IT1149328B (it) 1986-12-03
NO830948L (no) 1983-03-17
FI833099L (fi) 1983-08-31
NO159696C (no) 1989-02-01
DK128283A (da) 1983-03-21

Similar Documents

Publication Publication Date Title
GB2123695B (en) Orally administrable pharmaceutical compositions
DE3277520D1 (en) Pharmaceutical multiple-units formulation
KR930702963A (ko) 장질환 치료를 위한 서방성 경구 투약 형태
US3431338A (en) Coated dosage form adapted to oral emetine or dehydroemetine therapy
EP0108218A3 (de) Orale feste Verabreichungsform mit konstanter Wirkstoffabgabe pharmazeutischer Verbindungen, die sehr wasserlöslich sind
JPH04501411A (ja) 結腸選択的到達性を持つ経口医薬用製剤
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
PH20568A (en) Dietary and pharmaceutical uses of methyl sulfonylmethane and compositions comprising it
CA2132012A1 (en) Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997005903A3 (en) Composition for enhanced uptake of polar drugs from the colon
Goebell et al. Oroileal transit of slow release 5-aminosalicylic acid.
CA2038672A1 (en) Dosage form for delivering drug to the intestine
KR850700212A (ko) 서방성 약제학적 캼셀제
ES465906A1 (es) Un procedimiento de preparacion de comprimidos
WO1992016206A1 (en) The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
JPH04346930A (ja) 安定なアスピリン腸溶錠
US6004546A (en) Pharmaceutical composition containing bismuth-polyacrylic acid compounds
KR20020063871A (ko) 항 - 염증성 약학적 제제형
KR880007066A (ko) 우라피딜의 약제 형태
GB1463955A (en) Compositions containing prostaglandins
Tabata et al. Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)
Roncucci et al. Biodegradations of the Hydroxamic Acid Group of pn-Butoxyphenylacethydroxamic Acid (Bufexamac) in Various Animal Species
Tytgat Future clinical development of sucralfate
DIGNASS et al. Sulphasalazine, mesalazine and
TH31107B (th) ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน